Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients

15Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

Cellular immunotherapies have emerged as a successful therapeutic approach to fight a wide range of human diseases, including cancer. However, responses are limited to few patients and tumor types. An in-depth understanding of the complexity and dynamics of cellular immunotherapeutics, including what is behind their success and failure in a patient, the role of other immune cell types and molecular biomarkers in determining a response, is now paramount. As the cellular immunotherapy arsenal expands, whole-body non-invasive molecular imaging can shed a light on their in vivo fate and contribute to the reliable assessment of treatment outcome and prediction of therapeutic response. In this review, we outline the non-invasive strategies that can be tailored toward the molecular imaging of cellular immunotherapies and immune-related components, with a focus on those that have been extensively tested preclinically and are currently under clinical development or have already entered the clinical trial phase. We also provide a critical appraisal on the current role and consolidation of molecular imaging into clinical practice.

Cite

CITATION STYLE

APA

Volpe, A., Adusumilli, P. S., Schöder, H., & Ponomarev, V. (2022, September 22). Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients. Journal for ImmunoTherapy of Cancer. BMJ Publishing Group. https://doi.org/10.1136/jitc-2022-004902

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free